Alzheimer Disease (AD), the most common type of dementia, is characterized by progressive loss of memory and decline of other cognitive abilities that eventually interfere with social functioning. Currently, there are no effective treatments that reverse or substantially slow the progression of AD. The development of therapeutics for AD is plagued by multiple obstacles, including poor translation of pharmacology from cells to humans. Methods are needed to accelerate evaluation of candidate drugs to address the burgeoning prevalence of AD in aging populations.
